Study of coagulation factor activities in apheresed thawed fresh frozen plasma at 1–6°C for five days

2006 ◽  
Vol 21 (4) ◽  
pp. 224-226 ◽  
Author(s):  
Rameshwar S. Sidhu ◽  
Tuan Le ◽  
Brad Brimhall ◽  
Hannis Thompson
Keyword(s):  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Fresh Frozen ◽  
Frozen Plasma

Perioperative management of coagulation

2006 ◽  
Vol 26 (S 02) ◽  
pp. S3-S14 ◽  
Author(s):  
P. Innerhofer
Keyword(s):  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Laboratory Evaluation ◽  
Blood Component ◽  
Actual Case ◽  
Fresh Frozen ◽  
Coagulation Factor Concentrates ◽  
Hemostatic Therapy ◽  
Frozen Plasma

SummaryGuidelines of official societies for diagnosis and therapy of intraoperatively occurring hypocoagulability rely mainly on data of patients receiving whole blood transfusions. They recommend -provided that laboratory evaluation shows deficiency (values >1.5 fold normal)- administration of fresh frozen plasma, cryoprecipitate and platelet concentrates (platelet count <50 000 or <100 000/μl). This article describes the pathogenesis of coagulopathy in the light of the special intraoperative setting, emphasizes recent changes of blood component preparation, transfusion triggers, effects of volume therapy and challenges standard laboratory assays as reliable guide for intraoperative hemostatic therapy. The role of thrombelastographic monitoring is discussed as well as an alternative strategy to compensate deficiencies by the use of coagulation factor concentrates instead of or in addition to transfusion of FFP, a new concept which is illustrated by the presentation of an actual case report.

scholarly journals Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma

Blood ◽  
1992 ◽  
Vol 79 (3) ◽  
pp. 826-831 ◽  
Author(s):  
B Horowitz ◽  
R Bonomo ◽  
AM Prince ◽  
SN Chin ◽  
B Brotman ◽  
...  
Keyword(s):  
Sindbis Virus ◽  
Animal Studies ◽  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Complete Inactivation ◽  
Virus Safety ◽  
Fresh Frozen ◽  
History Of ◽  
Triton X ◽  
Frozen Plasma

Abstract Fresh frozen plasma (FFP) is prepared in blood banks world-wide as a by- product of red blood cell concentrate preparation. Appropriate clinical use is for coagulation factor disorders where appropriate concentrates are unavailable and when multiple coagulation factor deficits occur such as in surgery. Viral safety depends on donor selection and screening; thus, there continues to be a small but defined risk of viral transmission comparable with that exhibited by whole blood. We have prepared a virus sterilized FFP (S/D-FFP) by treatment of FFP with 1% tri(n-butyl)phosphate (TNBP) and 1% Triton X-100 at 30 degrees C for 4 hours. Added reagents are removed by extraction with soybean oil and chromatography on insolubilized C18 resin. Treatment results in the rapid and complete inactivation of greater than or equal to 10(7.5) infectious doses (ID50) of vesicular stomatitis virus (VSV) and greater than or equal to 10(6.9) ID50 of sindbis virus (used as marker viruses), greater than or equal to 10(6.2) ID50 of human immunodeficiency virus (HIV), greater than or equal to 10(6) chimp infectious doses (CID50) of hepatitis B virus (HBV), and greater than or equal to 10(5) CID50 of hepatitis C virus (HCV). Immunization of rabbits with S/D-FFP and subsequent adsorption of elicited antibodies with untreated FFP confirmed the absence of neoimmungen formation. Coagulation factor content was comparable with that found in FFP. Based on these laboratory and animal studies, together with the extensive history of the successful use of S/D-treated coagulation factor concentrates, we conclude that replacement of FFP with S/D-FFP, prepared in a manufacturing facility, will result in improved virus safety and product uniformity with no loss of efficacy.

Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies

Transfusion ◽  
2005 ◽  
Vol 45 (8) ◽  
pp. 1362-1372 ◽  
Author(s):  
Pedro De Alarcon ◽  
Richard Benjamin ◽  
Marion Dugdale ◽  
Craig Kessler ◽  
Rinah Shopnick ◽  
...  
Keyword(s):  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Pathogen Inactivation ◽  
Fresh Frozen ◽  
Frozen Plasma

scholarly journals Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy

Critical Care ◽  
2011 ◽  
Vol 15 (2) ◽  
pp. R83 ◽  
Author(s):  
Herbert Schöchl ◽  
Ulrike Nienaber ◽  
Marc Maegele ◽  
Gerald Hochleitner ◽  
Florian Primavesi ◽  
...  
Keyword(s):  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Fresh Frozen ◽  
Factor Concentrate ◽  
Frozen Plasma

scholarly journals Concentrated lyophilized plasma used for reconstitution of whole blood leads to higher coagulation factor activity but unchanged thrombin potential compared with fresh-frozen plasma

Transfusion ◽  
2017 ◽  
Vol 57 (7) ◽  
pp. 1763-1771 ◽  
Author(s):  
Giacomo E. Iapichino ◽  
Martin Ponschab ◽  
Janne Cadamuro ◽  
Susanne Süssner ◽  
Christian Gabriel ◽  
...  
Keyword(s):  
Whole Blood ◽  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Factor Activity ◽  
Fresh Frozen ◽  
Frozen Plasma

scholarly journals Coagulation Factor Activities Changes Over 5 Days in Thawed Fresh Frozen Plasma Stored at Different Initial Storage Temperatures

2017 ◽  
Vol 34 (3) ◽  
pp. 510-516 ◽  
Author(s):  
Siti Salmah Noordin ◽  
Faraizah Abdul Karim ◽  
Wan Mohd Zahiruddin bin Wan Mohammad ◽  
Abdul Rahim Hussein
Keyword(s):  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Fresh Frozen ◽  
Initial Storage ◽  
Storage Temperatures ◽  
Frozen Plasma

scholarly journals Coagulation profile of human COVID-19 convalescent plasma

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Allan M. Klompas ◽  
Noud van Helmond ◽  
Justin E. Juskewitch ◽  
Rajiv K. Pruthi ◽  
Matthew A. Sexton ◽  
...  
Keyword(s):  
Coagulation Factor ◽  
Protein S ◽  
Coagulation Factors ◽  
Fresh Frozen Plasma ◽  
Thrombin Time ◽  
Fresh Frozen ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Plasmin Inhibitor ◽  
Frozen Plasma

AbstractConvalescent plasma is used to treat COVID-19. There are theoretical concerns about the impact of pro-coagulant factors in convalescent plasma on the coagulation cascade particularly among patients with severe COVID-19. The aim of this study was to evaluate the coagulation profile of COVID-19 convalescent plasma. Clotting times and coagulation factor assays were compared between fresh frozen plasma, COVID-19 convalescent plasma, and pathogen-reduced COVID-19 convalescent plasma. Measurements included prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, D-dimer, von Willebrand factor activity, von Willebrand factor antigen, coagulation factors II, V, VII–XII, protein S activity, protein C antigen, and alpha-2 plasmin inhibitor. Clotting times and coagulation factor assays were not different between COVID-19 convalescent plasma and fresh frozen plasma, except for protein C antigen. When compared to fresh frozen plasma and regular convalescent plasma, pathogen reduction treatment increased activated partial thromboplastin time and thrombin time, while reducing fibrinogen, coagulation factor II, V, VIII, IX, X, XI, XII, protein S activity, and alpha-2 plasmin inhibitor. The coagulation profiles of human COVID-19 convalescent plasma and standard fresh frozen plasma are not different. Pathogen reduced COVID-19 convalescent plasma is associated with reduction of coagulation factors and a slight prolongation of coagulation times, as anticipated. A key limitation of the study is that the COVID-19 disease course of the convalesced donors was not characterized.

Sign in / Sign up

Export Citation Format

Share Document